Blenrep (Belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple Myeloma

Zai Lab receives U.S. FDA fast track designation for ZL-1310, a DLL3-targeted ADC, for treatment...

CPO301 granted the third fast track designation by US FDA for the treatment of adult...

Avenzo Therapeutics announces FDA clearance of Investigational New Drug application for AVZO-1418, a potential best-in-class,...

Fourth NDA for Kelun-Biotech’s TROP2 ADC Sacituzumab tirumotecan (sac-TMT) accepted by the Center for Drug...

Antengene enters into a global clinical collaboration with MSD to evaluate ATG-022 (CLDN18.2 ADC) in...